, Volume 58, Supplement 2, pp 85–91 | Cite as

Use of Quinolones in Osteomyelitis and Infected Orthopaedic Prosthesis

  • Daniel P. Lew
  • Francis A. Waldvogel
Oral Presentations Review Article


The present review provides an updated critical analysis of the use of quinolones in osteomyelitis and orthopaedic prosthetic infections. Only papers published in peer-reviewed journals and related to the following areas were selected: experimental osteomyelitis, penetration of quinolones into human bone, and clinical use in comparative and noncomparative studies. Local drug carriers impregnated with quinolones allow high local antibiotic concentrations to be achieved in experimental systems. Considerable clinical experience has been gained mostly with ciprofloxacin and ofloxacin. Cumulated results in clinical trials show clinical success rates of more than 90% in osteomyelitis caused by Enterobacteriaceae. The combination of quinolones and rifampicin for the treatment of staphylococcal osteomyelitis as well as orthopaedic prosthetic infections appears very promising in clinical studies with a small number of patients. However, further comparative studies using quinolones as single agents or in combination (versus standard parenteral therapy) remain necessary in osteomyelitis due to Staphylococcus aureus or Pseudomonas aeruginosa. In particular, studies with the newer quinolones should be strongly encouraged in acute or chronic osteomyelitis and in more complicated situations such as diabetic osteomyelitis or foreign-body infection.


Adis International Limited Osteomyelitis Ofloxacin Quinolones Antimicrob Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Waldvogel FA. Use of quinolones for the treatment of osteomyelitis and septic arthritis. Rev Infect Dis 1989; 11: S1259–63PubMedCrossRefGoogle Scholar
  2. 2.
    Lew DP, Waldvogel FA. Use of quinolones for treatment of osteomyelitis and septic arthritis. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents, 2 ed. Washington, D.C.: American Society for Microbiology, 1993: 371–9Google Scholar
  3. 3.
    Lew DP, Waldvogel FA. Quinolones and osteomyelitis: state-of-the-art. Drugs 1995; 49 Suppl. 2: 100–11CrossRefGoogle Scholar
  4. 4.
    Desplaces N, Acar JF. New quinolones in the treatment of joint and bone infections. Rev Infect Dis 1988; 10 Suppl. 1: S179–83PubMedCrossRefGoogle Scholar
  5. 5.
    Hessen MT, Levison ME. Ciprofloxacin for the treatment of osteomyelitis: a review. J Foot Surg 1989; 28: 100–5PubMedGoogle Scholar
  6. 6.
    Norrby SR. Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review. Scand J Infect Dis 1989; 60 Suppl.: 74–8Google Scholar
  7. 7.
    Wispelwey B, Scheid WM. Ciprofloxacin in the treatment of Staphylococcus aureus osteomyelitis. A review. Diagn Microbiol Infect Dis 1990; 13: 169–71CrossRefGoogle Scholar
  8. 8.
    Gentry LO. Oral antimicrobial therapy for osteomyelitis [editorial] (see comments). Ann Intern Med 1991; 114: 986–7PubMedGoogle Scholar
  9. 9.
    Garcia Rosario LN, Ramirez Ronda CH. The use of ciprofloxacin in patients with osteomyelitis associated with vascular insufficiency. El uso de ciprofloxacin en pacientes con osteomielitis asociada a insuficiencia vascular. Bol Assoc Med P R 1990; 82: 125–8Google Scholar
  10. 10.
    Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin Infect Dis 1997; 25: 1327–33PubMedCrossRefGoogle Scholar
  11. 11.
    Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336: 999–1007PubMedCrossRefGoogle Scholar
  12. 12.
    Mader JT, Norden C, Nelson JD, et al. Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl. 1: S155–61PubMedCrossRefGoogle Scholar
  13. 13.
    Norden C, Nelson JD, Mader JT, et al. Evaluation of new anti-infective drugs for the treatment of infectious arthritis in adults. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl. 1: S167–71PubMedCrossRefGoogle Scholar
  14. 14.
    Cowan ST, Steel KJ. Cowan and Steel’s Manual for the identification of medical bacteria. Cambridge: Cambridge University Press, 1993Google Scholar
  15. 15.
    Norden CW, Shinners E. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. J Infect Dis 1995; 151:291–4CrossRefGoogle Scholar
  16. 16.
    Henry NK, Rouse MS, Whitesell AL, et al. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987; 82:73–5PubMedGoogle Scholar
  17. 17.
    Dworkin R, Modin G, Kunz S, et al. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob Agents Chemother 1990; 34: 1014–6PubMedCrossRefGoogle Scholar
  18. 18.
    Lucet JC, Herrmann M, Rohner P, et al. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemotherx 1990; 34: 2312–7CrossRefGoogle Scholar
  19. 19.
    Chuard C, Herrmann M, Vaudaux P, et al. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991; 35: 2611–6PubMedCrossRefGoogle Scholar
  20. 20.
    Crémieux AC, Mghir AS, Bleton R, et al. Efficacy of sparfloxacin and autoradio graphic diffusion pattern of [14C]sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother 1996; 40: 2111–6PubMedGoogle Scholar
  21. 21.
    Waldvogel FA. Infections osseuses. In: Fabre J, editor. Thérapeutique médicale Maladies du squelette, Paris: Flammarion, 1978: 849–51Google Scholar
  22. 22.
    Wittmann DH, Kotthaus E. Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage. Infection 1986; 14 Suppl. 4: S270–3PubMedCrossRefGoogle Scholar
  23. 23.
    Meissner A, Borner K, Koeppe P. Concentrations of ofloxacin in human bone and in cartilage. J Antimicrob Chemother 1990; 26 Suppl. D: 69–74PubMedCrossRefGoogle Scholar
  24. 24.
    Fong IW, Ledbetter WH, Vandenbroucke AC, et al. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother 1986; 29: 405–8PubMedCrossRefGoogle Scholar
  25. 25.
    Meissner A, Borner K. Konzentration von ciprofloxacin im knochengewebe concentration of ciproloxacin in bone tissue. Akt Traumatol 1993; 23: 80–4Google Scholar
  26. 26.
    Coignard S, Renard C, Lortat-Jacob A. Diffusion de la pefloxacine dans le tissu osseux humain. Médecine et Maladies Infectieuses 1986; 7: 471–4CrossRefGoogle Scholar
  27. 27.
    Dellamonica P, Bernard E, Etesse H, Garraffo R. The diffusion of pefloxacin into bone and the treatment of osteomyelitis. J Antimicrob Chemother 1986; 17 Suppl. B: 93–102PubMedCrossRefGoogle Scholar
  28. 28.
    Nicolau DP, Nie L, Tessier PR, et al. Prophylaxis of acute osteomyelitis with absorbable ofloxacin-impregnated beads. Antimicrob Agents Chemother 1998; 42: 840–2PubMedGoogle Scholar
  29. 29.
    Nie L, Nicolau DP, Tessier PR, et al. Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment. J Orthop Res 1998; 16: 76–9PubMedCrossRefGoogle Scholar
  30. 30.
    Yamaguti A, Trevisanello C, Lobo IM, et al. Oral ciprofloxacin for treatment of chronic osteomyelitis. Int J Clin Pharmacol Res 1993; 13:75–9PubMedGoogle Scholar
  31. 31.
    Trujillo IZ, Valladares G, Nava A. Ciprofloxacin in the treatment of chronic osteomyelitis in adults. Drugs 1993; 45 Suppl. 3: 454–5CrossRefGoogle Scholar
  32. 32.
    Gilbert DN, Tice AD, Marsh PK, et al. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic Gram-negative bacilli. Am J Med 1987; 82: 254–8PubMedCrossRefGoogle Scholar
  33. 33.
    Hessen MT, Ingerman MJ, Kaufman DH, et al. Clinical efficacy of ciprofloxacin therapy for Gram-negative bacillary osteomyelitis. Am J Med 1987; 82:262–5PubMedGoogle Scholar
  34. 34.
    Nix DE, Cumbo TJ, Kuritzky P, et al. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. Am J Med 1987; 82: 146–53Google Scholar
  35. 35.
    Greenberg RN, Kennedy DJ, Reilly PM, et al. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother 1987; 31: 151–5PubMedCrossRefGoogle Scholar
  36. 36.
    Swedish Study Group. Therapy of acute and chronic Gram-negative osteomyelitis with ciprofloxacin. J Antimicrob Chemother 1988; 22: 221–8CrossRefGoogle Scholar
  37. 37.
    Hoogkamp Korstanje JA, van Bottenburg HA, van Bruggen J, et al. Treatment of chronic osteomyelitis with ciprofloxacin. J Antimicrob Chemother 1989; 23: 427–32PubMedCrossRefGoogle Scholar
  38. 38.
    Dan M, Siegman Igra Y, Pitlik S, et al. Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis. Antimicrob Agents Chemother 1990; 34: 849–52PubMedCrossRefGoogle Scholar
  39. 39.
    Peterson LR, Lissack LM, Canter K, et al. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med 1989; 86: 801–8PubMedCrossRefGoogle Scholar
  40. 40.
    Ketterl R, Beckurts T, Stubinger B, et al. Use of ofloxacin in open fractures and in the treatment of post-traumatic osteomyelitis. J Antimicrob Chemother 1988; 22 Suppl. C: 159–66PubMedGoogle Scholar
  41. 41.
    Seibold R, Betz A. Treatment of posttraumatic osteitis with intravenous ofloxacin. Clin Ther 1991; 13: 457–9PubMedGoogle Scholar
  42. 42.
    Ketterl R, Wittwer W, Beckurts T. Ofloxacin zur antibiotikatherapie bei der chronischen posttraumatischen Osteitis. Die Medizinische Welt 1995; 46: 505–11Google Scholar
  43. 43.
    Galanakis N, Giamarellou H, Moussas T, et al. Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. J Antimicrob Chemother 1997; 39: 241–6PubMedCrossRefGoogle Scholar
  44. 44.
    Greenberg RN, Tice AD, Marsh PK, et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med 1987; 82: 266–9PubMedCrossRefGoogle Scholar
  45. 45.
    Mader JT, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J Bone Joint Surg 1990; 72: 104–10PubMedGoogle Scholar
  46. 46.
    Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 1990; 34: 40–3PubMedCrossRefGoogle Scholar
  47. 47.
    Gentry LO, Rodriguez Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother 1991; 35: 538–41PubMedCrossRefGoogle Scholar
  48. 48.
    Defino HLA, Moretti JE, Rodrigues-Fuentes AE. Comparative study of the efficacy of pefloxacin versus cephalotin/cephalexin + gentamicin in the treatment of post-traumatic or post-surgical osteomyelitis. Rev Bras Med 1992; 49(10): 785–90Google Scholar
  49. 49.
    Tenover FC, Arbeit R, Archer G, et al. Comparison of traditional and molecular methods of typing isolates of Staphylococeus aureus. J Clin Microbiol 1994; 32: 407–15PubMedGoogle Scholar
  50. 50.
    Caputo GM, Cavanagh PR, Ulbrecht JS, et al. Assessment and management of foot disease in patients with diabetes. New Engl J Med 1994; 331(13): 854–60PubMedCrossRefGoogle Scholar
  51. 51.
    Lipsky BA, Baker PD, Landon GC, et al. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis 1997; 24: 643–8PubMedCrossRefGoogle Scholar
  52. 52.
    Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/ sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18: 683–93PubMedCrossRefGoogle Scholar
  53. 53.
    Brandt CM, Sistrunk WW, Duffy MC, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997; 24: 914–9PubMedCrossRefGoogle Scholar
  54. 54.
    Drancourt M, Stein A, Argenson JN, et al. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993; 37: 1214–8PubMedCrossRefGoogle Scholar
  55. 55.
    Widmer AF, Gaechter A, Ochsner PE, et al. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992; 14: 1251–3PubMedCrossRefGoogle Scholar
  56. 56.
    Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections — a randomized controlled trial. JAMA 1998; 279: 1537–41PubMedCrossRefGoogle Scholar
  57. 57.
    Schlichting C, Branger C, Fournier J-M, et al. Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: Resolution of clonal relationships. J Clin Microbiol 1993; 31: 227–32PubMedGoogle Scholar
  58. 58.
    Brouqui P, Rousseau MC, Stein A, et al. Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob Agents Chemother 1995; 39: 2423–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Division of Infectious Diseases and Clinic of Medicine 2, Department of MedicineGeneva University HospitalGeneva 14Switzerland

Personalised recommendations